Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 6/20 | 1.00 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | CNR2 | P34972 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1044904 | 1.00 | CNR1 (1.00) | CNR1OPRL1KCNH2CNR2 | |
| SCHEMBL13315383 | 0.94 | CNR1 (0.89) | CNR1OPRL1KCNH2CNR2 | |
| SCHEMBL25509577 | 0.79 | CNR1 (0.66) | CNR1OPRL1KCNH2CNR2 | |
| SCHEMBL25283366 | 0.79 | CNR1 (0.64) | CNR1OPRL1CNR2 | |
| SCHEMBL24208707 | 0.78 | CNR1 (0.65) | CNR1OPRL1KCNH2CNR2 | |
| SCHEMBL3385634 | 0.78 | CNR1 (0.68) | CNR1OPRL1KCNH2CNR2 | |
| SCHEMBL30513088 | 0.78 | CNR1 (0.68) | CNR1OPRL1KCNH2CNR2 | |
| SCHEMBL1044572 | 0.77 | CNR1 (1.00) | CNR1OPRL1KCNH2CNR2 | |
| SCHEMBL1044571 | 0.77 | CNR1 (1.00) | CNR1OPRL1KCNH2CNR2 | |
| SCHEMBL24208913 | 0.76 | CNR1 (0.71) | CNR1OPRL1KCNH2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2739262-B1 | USE OF A CB1 RECEPTOR ANTAGONIST AS A WHITENING AND/OR ANTI-BROWNING AGENT FOR KERATIN MATERIAL | OREAL (FR) | 2017-09-27 | — | — | EP | claimed |
| EP-2739262-B1 | USE OF A CB1 RECEPTOR ANTAGONIST AS A WHITENING AND/OR ANTI-BROWNING AGENT FOR KERATIN MATERIAL | OREAL (FR) | 2017-09-27 | — | — | EP | disclosed |
| US-9662320-B2 | Antagonists of the cannabinoid receptor CB1 for use in the treatment of diseases associated with neuronal dendritic abnormalities | UNIVERSITAT POMPEU FABRA (ES) | 2017-05-30 | — | — | US | disclosed |
| US-9662320-B2 | Antagonists of the cannabinoid receptor CB1 for use in the treatment of diseases associated with neuronal dendritic abnormalities | UNIVERSITAT POMPEU FABRA (ES) | 2017-05-30 | — | — | US | disclosed |
| US-9662320-B2 | Antagonists of the cannabinoid receptor CB1 for use in the treatment of diseases associated with neuronal dendritic abnormalities | UNIVERSITAT POMPEU FABRA (ES) | 2017-05-30 | — | — | US | disclosed |
| US-9622995-B2 | Treatment of disorders associated with G protein-coupled receptor 35 (GPR35) | Temple University—Of the Commonwealth System of Higher Education (US) | 2017-04-18 | — | — | US | disclosed |
| US-20160067235-A1 | Antagonists of the Cannabinoid Receptor CB1 for Use in the Treatment of Diseases Associated with Neuronal Dendritic Abnormalities | UNIVERSITAT POMPEU FABRA (ES) | 2016-03-10 | — | — | US | disclosed |
| US-20160067235-A1 | Antagonists of the Cannabinoid Receptor CB1 for Use in the Treatment of Diseases Associated with Neuronal Dendritic Abnormalities | UNIVERSITAT POMPEU FABRA (ES) | 2016-03-10 | — | — | US | disclosed |
| US-20160067235-A1 | Antagonists of the Cannabinoid Receptor CB1 for Use in the Treatment of Diseases Associated with Neuronal Dendritic Abnormalities | UNIVERSITAT POMPEU FABRA (ES) | 2016-03-10 | — | — | US | disclosed |
| US-20150265561-A1 | TREATMENT OF DISORDERS ASSOCIATED WITH G PROTEIN-COUPLED RECEPTOR 35 (GPR35) | NATIONAL INSTITUTES OF HEALTH | 2015-09-24 | — | — | US | disclosed |
| US-9040583-B2 | Treatment of disorders associated with G protein-coupled receptor 35 (GPR35) | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2015-05-26 | — | — | US | disclosed |
| US-20120122987-A1 | TREATMENT OF DISORDERS ASSOCIATED WITH G PROTEIN-COUPLED RECEPTOR 35 (GPR35) | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2011011235-A1 | TREATMENT OF DISORDERS ASSOCIATED WITH G PROTEIN-COUPLED RECEPTOR 35 (GPR35) | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122987-A1 | TREATMENT OF DISORDERS ASSOCIATED WITH G PROTEIN-COUPLED RECEPTOR 35 (GPR35) | GPR35, GPR68, GRM5 | CNR1 212/4885OPRL1 24/4885KCNH2 2614/4885 |
| US-20150265561-A1 | TREATMENT OF DISORDERS ASSOCIATED WITH G PROTEIN-COUPLED RECEPTOR 35 (GPR35) | GPR35, GPR68, GRM5 | CNR1 212/4885OPRL1 24/4885KCNH2 2614/4885 |
| US-20160067235-A1 | Antagonists of the Cannabinoid Receptor CB1 for Use in the Treatment of Diseases Associated with Neuronal Dendritic Abnormalities | CNR1, CNR2, DBN1 | CNR1 1/4885OPRL1 55/4885KCNH2 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.